| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 62.35 | -6 |
| Intrinsic value (DCF) | 148.52 | 124 |
| Graham-Dodd Method | n/a | |
| Graham Formula | n/a |
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.